Head and Neck Cancer is cancer that arises in the head or neck region (in the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx [voice box]).
Osteoporosis patients who suffer drug side effects that result in painful exposed bone in the jaw could benefit if they are treated with one of the more comprehensive surgical options that could lower the risk of relapse and repeat surgery, according to a study published in the July issue of the Journal of Oral and Maxillofacial Surgery.
The immunotherapy nivolumab is kinder than chemotherapy for people with advanced head and neck cancer - easing many of the negative effects of the disease on patients' quality of life.
Radiation therapy is one of the most common treatments used to fight cancer, with an estimated 500,000 people each year receiving radiation therapy either alone or in combination with other treatments.
A novel vaccine therapy can generate immune responses in patients with head and neck squamous cell carcinoma (HNSCCa), according to researchers at the Abramson Cancer Center of the University of Pennsylvania.
The U.S. Food and Drug Administration today granted accelerated approval to a treatment for patients whose cancers have a specific genetic feature (biomarker).
The American Society for Radiation Oncology today issued a new clinical guideline for the management of oropharyngeal cancer.
ANGLE plc, the specialist medtech company, is delighted to announce that the University of Athens and Attikon University Hospital, Greece are today presenting highly encouraging results from their work with ANGLE’s Parsortix system in head and neck squamous cell carcinomas at the American Association for Cancer Research conference 2017, in Washington DC.
Higher or lower levels of certain immune cells in cancer patients may be associated with how well they respond to immunotherapy, according to preliminary results of a study conducted by researchers at the University of Pittsburgh Cancer Institute.
An advanced form of image-guided radiation therapy, known as intensity modulated proton therapy, has shown early promise for the treatment of recurrent lung cancer, according to new research from The University of Texas MD Anderson Cancer Center.
Targeting cancer stem cells may be a more effective way to overcome cancer resistance and prevent the spread of squamous cell carcinoma — the most common head and neck cancer and the second-most common skin cancer, according to a new study by cancer researchers at the UCLA School of Dentistry.
Cervical cancer is the leading cause of cancer deaths for women low- and middle-income countries, including Botswana, where 75 percent of cervical cancer patients suffer from advanced forms of the disease.
East Asian female breast cancer patients receiving radiotherapy have a higher risk of developing second primary lung cancer.
A team of researchers at the Research Institute of the McGill University Health Centre has found an epigenetic modification that might be the cause of 15% of adult cancers of the throat linked to alcohol and tobacco use.
Results of an initial study of tumors from patients with lung cancer or head and neck cancer suggest that the widespread acquired resistance to immunotherapy drugs known as checkpoint inhibitors may be due to the elimination of certain genetic mutations needed to enable the immune system to recognize and attack malignant cells.
Researchers have found that people with advanced head and neck squamous cell carcinoma and the KRAS-variant inherited genetic mutation have significantly improved survival when given a short course of the drug cetuximab in combination with standard chemotherapy and radiation.
A new study suggests the possibility of predicting at its earliest stages when a type of head and neck cancer will come back.
A number of genetic variants associated with susceptibility to oral cavity and pharyngeal cancer have been described in an international study published in the journal Nature Genetics.
Results of the largest Canadian clinical trial to date comparing standard treatment for locally advanced squamous cell head and neck cancer with an experimental treatment, did not show the new treatment is superior.
Patients wait an average of four months before seeking a cancer diagnosis, researchers report at the ESMO ASIA 2016 Congress in Singapore.
Researchers at the University of Cincinnati have discovered that an ion channel, active within T cells (white blood cells), could be targeted to reduce the growth of head and neck cancers.